In today’s briefing:
- Global Oil Market 2025: US, OPEC+ and Much More..
- APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin
Global Oil Market 2025: US, OPEC+ and Much More..
- Global oil demand growth is slowing, with projections to reach 103.8 mb/d in 2025. OPEC+ is delaying production increases amid weaker demand & rising competition from non-OPEC producers like U.S.
- Geopolitical instability, a renewable energy shift, and challenges like China’s slowdown and high global interest rates are reshaping oil market dynamics, affecting prices and economic strategies.
- OPEC’s influence is waning as non-OPEC players expand and renewable energy adoption grows. The oil market’s evolution highlights the urgent need for diversification in energy strategies.
APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin
- After two rejections, Mesoblast has finally received FDA approval for its first drug. Celltrion has received FDA approval for its Stelara biosimilar, which will be launched in February 2025.
- Peptidream has become eligible for a milestone payment. Sumitomo Pharma is strengthening R&D for regenerative medicine and cell therapy business. Astellas Pharma in-licenses technology for developing neurology drugs.
- Hansoh Pharmaceutical granted an exclusive global license to Merck for its pre-clinical drug candidate. Lupin received FDA approval to market generic version of blockbuster Descovy tablets.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
